Anika Therapeutics Stock Performance
| ANIK Stock | USD 15.42 0.20 1.28% |
The firm shows a Beta (market volatility) of 1.14, which signifies a somewhat significant risk relative to the market. Anika Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Anika Therapeutics is expected to follow. At this point, Anika Therapeutics has a negative expected return of -0.0725%. Please make sure to confirm Anika Therapeutics' skewness, and the relationship between the treynor ratio and rate of daily change , to decide if Anika Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Anika Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent forward indicators, Anika Therapeutics is not utilizing all of its potentials. The recent stock price mess, may contribute to short-term losses for the institutional investors. ...more
Actual Historical Performance (%)
One Day Return (1.28) | Five Day Return (3.20) | Year To Date Return (4.87) | Ten Year Return (62.58) | All Time Return 340.57 |
1 | Acquisition by David Colleran of 7662 shares of Anika Therapeutics subject to Rule 16b-3 | 12/24/2024 |
2 | Caligan Partners LP Acquires Significant Stake in Verrica Pharmaceuticals Inc | 02/13/2025 |
3 | Avidity Biosciences, Inc. Reports Q4 Loss, Tops Revenue Estimates | 02/27/2025 |
4 | Syndax Pharmaceuticals Reports Q4 Loss, Lags Revenue Estimates | 03/03/2025 |
5 | Acquisition by Cheryl Blanchard of 20002 shares of Anika Therapeutics subject to Rule 16b-3 | 03/10/2025 |
6 | Disposition of 20002 shares by Cheryl Blanchard of Anika Therapeutics subject to Rule 16b-3 | 03/11/2025 |
7 | Anika Therapeutics Non-GAAP EPS of -0.03 misses by 0.12, revenue of 30.6M beats by 1.6M | 03/12/2025 |
8 | Anika Therapeutics Inc Q4 2024 Earnings Call Highlights Navigating Growth and Challenges | 03/13/2025 |
9 | Anika Therapeutics Full Year 2024 Earnings Misses Expectations | 03/14/2025 |
10 | Disposition of 1068 shares by Anne Nunes of Anika Therapeutics at 15.91 subject to Rule 16b-3 | 03/18/2025 |
11 | Acquisition by David Colleran of 13669 shares of Anika Therapeutics subject to Rule 16b-3 | 03/19/2025 |
12 | Quinta Brunson files to divorce husband Kevin Anik after three years of marriage | 03/21/2025 |
| Begin Period Cash Flow | 72.9 M |
Anika |
Anika Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,633 in Anika Therapeutics on December 24, 2024 and sell it today you would lose (91.00) from holding Anika Therapeutics or give up 5.57% of portfolio value over 90 days. Anika Therapeutics is currently does not generate positive expected returns and assumes 2.1294% risk (volatility on return distribution) over the 90 days horizon. In different words, 19% of stocks are less volatile than Anika, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Anika Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Anika Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Anika Therapeutics, and traders can use it to determine the average amount a Anika Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.034
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ANIK |
Estimated Market Risk
| 2.13 actual daily | 19 81% of assets are more volatile |
Expected Return
| -0.07 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Anika Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Anika Therapeutics by adding Anika Therapeutics to a well-diversified portfolio.
Anika Therapeutics Fundamentals Growth
Anika Stock prices reflect investors' perceptions of the future prospects and financial health of Anika Therapeutics, and Anika Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Anika Stock performance.
| Return On Equity | -0.0482 | ||||
| Return On Asset | -0.0119 | ||||
| Profit Margin | (0.47) % | ||||
| Operating Margin | (0) % | ||||
| Current Valuation | 189.04 M | ||||
| Shares Outstanding | 14.18 M | ||||
| Price To Earning | 42.30 X | ||||
| Price To Book | 1.42 X | ||||
| Price To Sales | 1.82 X | ||||
| Revenue | 119.91 M | ||||
| Gross Profit | 76.6 M | ||||
| EBITDA | (5.1 M) | ||||
| Net Income | (56.38 M) | ||||
| Cash And Equivalents | 87.78 M | ||||
| Cash Per Share | 6.01 X | ||||
| Total Debt | 24.01 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 6.37 X | ||||
| Book Value Per Share | 10.68 X | ||||
| Cash Flow From Operations | 5.4 M | ||||
| Earnings Per Share | (0.60) X | ||||
| Market Capitalization | 218.59 M | ||||
| Total Asset | 202.74 M | ||||
| Retained Earnings | 71.67 M | ||||
| Working Capital | 90.35 M | ||||
| Current Asset | 176.43 M | ||||
| Current Liabilities | 17.28 M | ||||
About Anika Therapeutics Performance
By examining Anika Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Anika Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Anika Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 197.92 | 283.42 | |
| Return On Tangible Assets | (0.29) | (0.28) | |
| Return On Capital Employed | (0.03) | (0.03) | |
| Return On Assets | (0.28) | (0.26) | |
| Return On Equity | (0.37) | (0.35) |
Things to note about Anika Therapeutics performance evaluation
Checking the ongoing alerts about Anika Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Anika Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Anika Therapeutics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 119.91 M. Net Loss for the year was (56.38 M) with profit before overhead, payroll, taxes, and interest of 76.6 M. | |
| Over 90.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from aol.com: Quinta Brunson files to divorce husband Kevin Anik after three years of marriage |
- Analyzing Anika Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Anika Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Anika Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Anika Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Anika Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Anika Therapeutics' stock. These opinions can provide insight into Anika Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.51) | Earnings Share (0.60) | Revenue Per Share | Quarterly Revenue Growth (0.29) | Return On Assets |
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.